1. Home
  2. ELTK vs TCRX Comparison

ELTK vs TCRX Comparison

Compare ELTK & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eltek Ltd.

ELTK

Eltek Ltd.

HOLD

Current Price

$8.59

Market Cap

76.9M

Sector

Technology

ML Signal

HOLD

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$1.01

Market Cap

64.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELTK
TCRX
Founded
1970
2018
Country
Israel
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.9M
64.1M
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
ELTK
TCRX
Price
$8.59
$1.01
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$8.50
AVG Volume (30 Days)
30.3K
694.9K
Earning Date
11-18-2025
11-12-2025
Dividend Yield
2.20%
N/A
EPS Growth
N/A
N/A
EPS
0.17
N/A
Revenue
$49,310,000.00
$8,423,000.00
Revenue This Year
$18.60
$286.83
Revenue Next Year
$9.04
N/A
P/E Ratio
$50.16
N/A
Revenue Growth
2.54
N/A
52 Week Low
$7.65
$0.88
52 Week High
$12.19
$3.21

Technical Indicators

Market Signals
Indicator
ELTK
TCRX
Relative Strength Index (RSI) 39.45 45.16
Support Level $8.42 $0.88
Resistance Level $8.87 $1.10
Average True Range (ATR) 0.38 0.07
MACD 0.02 0.03
Stochastic Oscillator 25.66 56.34

Price Performance

Historical Comparison
ELTK
TCRX

About ELTK Eltek Ltd.

Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. It manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. Its geographic areas are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: